ストックスクリーナーアプリを入手
7.60
52.00%
2.60
Aardvark Therapeutics Inc (AARD) 最新ニュース
What's going on with Aardvark Therapeutics stock on Wednesday? - MSN
[DEF 14A] Aardvark Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Aardvark Therapeutics (AARD) Cantor Global Healthcare Conference 2025 Summary - Quartr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc.AARD - AOL.com
Aardvark Therapeutics, Inc. Common Stock (NASDAQ: AARD) Stock Price, News & Analysis - Kalkine
AARD Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Navigates DevelopmentNet Profit Margin - dars.gov.et
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Dynamic Index - marketscreener.com
Aardvark Therapeutics (NASDAQ: AARD) asks shareholders to reprice 2.8M options - Stock Titan
Aardvark Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 3000E Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2500 Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) dropped from Russell 2000 Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Value Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 2500 Value Benchmark - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Aardvark Therapeutics, Inc.(NasdaqGS:AARD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Aardvark Therapeutics (AARD) Retreats 5.3% as Shares Test Key Support LevelsDouble EMA - dars.gov.et
Aardvark Therapeutics, Inc. Actuals & Estimates (NASDAQ:AARD) - TradingView
Aardvark Therapeutics, Inc. Actuals & Estimates (BOATS:AARD) - TradingView
Aardvark Therapeutics Company Profile & Introduction - Moomoo
AARD Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
Price to earnings forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
Price to book forward of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS - PR Newswire
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
Aardvark Therapeutics Leads The Charge With 2 Other Noteworthy Penny Stocks - simplywall.st
Aardvark Therapeutics Inc (AARD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aardvark Therapeutics Inc. (AARD) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Season Outlook - dars.gov.et
Aardvark Therapeutics (AARD) Gains 1.57% Amid Consolidation Near SupportTICK Divergence - dars.gov.et
Aardvark Therapeutics Inc (AARD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aardvark Therapeutics Inc (AARD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aardvark Therapeutics Inc (AARD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aardvark Therapeutics Inc (AARD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aardvark Therapeutics Inc (AARD) Institutional Confidence - TradingKey
Aardvark Therapeutics Inc (AARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aardvark Therapeutics Inc (AARD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aardvark Therapeutics Inc (AARD) Valuation: PE, PB & Fair Value Analysis - TradingKey
AARD Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Preview - newsline.com
Aardvark Therapeutics Inc. (AARD) Gains 7% as Stock Approaches Resistance LevelRisk Reward Setups - newsline.com
Aardvark Therapeutics Implements Executive Retention Bonus Agreements - TipRanks
Executive retention bonuses outlined at Aardvark Therapeutics (NASDAQ: AARD) - Stock Titan
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc.AARD - FinancialContent
Aardvark Therapeutics Insiders Lose Out As Stock Sinks To US$3.59 - simplywall.st
Lawsuit probes Aardvark Therapeutics after FDA halts key drug trials, causing stock to plummet. - Pluang
Aardvark Therapeutics (AARD) Slips 2.45% as Stock Tests Key Support at $3.41Elliott Wave Entry - newsline.com
Aardvark Therapeutics (AARD) Declines Over 4% as Stock Tests Key Support LevelsVolatility Skew - newsline.com
2.64%
大文字化:
|
ボリューム (24 時間):